Soy allergy due to cross reactions to major birch pollen allergen Bet v 1

被引:0
|
作者
Kleine-Tebbe, J. [1 ]
Herold, D. A. [1 ]
Vieths, S. [2 ]
机构
[1] AAZW, D-14050 Berlin, Germany
[2] Paul Ehrlich Inst, Abt Allergol, D-6070 Langen, Germany
关键词
food allergy; soy allergy; Gly m 4; birch pollen allergy; Bet v 1; cross reaction; PR-10 protein family; anaphylaxis;
D O I
暂无
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
The most prevalent soy allergy in Central Europe is based on birch pollen-related cross reactions. Due to structure similarities of birch pollen major allergen Bet v 1 and soy allergen Gly m 4, 75% of birch pollen-allergic subjects show serological IgE-mediated cross reactions to the soy protein Gly m 4 from the family of Bet v 1-homologue, pathogenesis-related (PR)-10 proteins. Interestingly, only 10% of birch pollen-allergic patients develop clinical symptoms after ingestion of non- or slighty processed soy products (soy flakes, soy milk, tofu, diatery powders with soy isolate). Predominantly local oropharyngeal symptoms can lead to massive and severe swellings of throat or facial areas with dramatic severity. In addition, systemic reactions with urticarial, gastrointestinal and cardiovascular symptoms have been described. A typical case history of reactions with quick onset after ingestion of mildly processed soy products together with a strong allergic sensitization to birch pollen represent highly suggestive diagnostic clues. Native soy products are more useful for skin testing than commercial soy extracts due to labile Gly in 4 and its low abundance of 0.01 - 0.1% in total soy protein. For the same reason crude soy extracts are not sensitive enough for allergen-specific IgE detection in case of suspected Gly m 4-induced soy allergy. Recently introduced recombinant Gly m 4 is superior in demonstrating specific IgE. In case of established birch pollen-associated, clinically relevant soy allergy non- or hardly processed soy products should be avoided. Subsequent declaration of soy products about potential risks for birch pollen-allergic subjects might be helpful for future avoidance and instant diagnosis of the usually unexpected reactions. Heated and strongly processed products like soy sauce, textured soy proteins, roasted soy beans or soy oil are unlikely to represent inherent risks due to their low Gly m 4 content. Soy allergy on the basis of birch pollen-related crossreactions should be publicized more frequently.
引用
收藏
页码:303 / 313
页数:13
相关论文
共 50 条
  • [1] Bioavailability of the major birch pollen allergen Bet v 1
    Ochs, S
    Wallmuth, A
    Kasche, A
    Weichenmeier, I
    Traidl-Hoffmann, C
    Huss-Marp, J
    Krämer, U
    Link, E
    Gebauer, G
    Schober, W
    Behrendt, H
    Buters, JTM
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 372 : 134 - 134
  • [2] Allergy vaccine development using the birch pollen major allergen Bet v 1 as example
    Wallner, M.
    Hauser, M.
    ALLERGOLOGIE, 2012, 35 (02) : 88 - 94
  • [3] Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1
    Mahler, V
    Vrtala, S
    Kuss, O
    Diepgen, TL
    Suck, R
    Cromwell, O
    Fiebig, H
    Hartl, A
    Thalhamer, J
    Schuler, G
    Kraft, D
    Valenta, R
    CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (01): : 115 - 122
  • [4] The History and Science of the Major Birch Pollen Allergen Bet v 1
    Breiteneder, Heimo
    Kraft, Dietrich
    BIOMOLECULES, 2023, 13 (07)
  • [5] Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen
    Menz, G
    Dolecek, C
    SchonheitKenn, U
    Ferreira, F
    Moser, M
    Schneider, T
    Suter, M
    BoltzNitulescu, G
    Ebner, C
    Kraft, D
    Valenta, R
    CLINICAL AND EXPERIMENTAL ALLERGY, 1996, 26 (01): : 50 - 60
  • [6] The major birch pollen allergen, Bet v 1, shows ribonuclease activity
    Bufe, A
    Spangfort, MD
    Kahlert, H
    Schlaak, M
    Becker, WM
    PLANTA, 1996, 199 (03) : 413 - 415
  • [7] Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination
    Vrtala, Susanne
    Fohr, Monika
    Campana, Raffaela
    Baumgartner, Christian
    Valent, Peter
    Valenta, Rudolf
    VACCINE, 2011, 29 (11) : 2140 - 2148
  • [8] In vitro and in vivo characterization of vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1
    Mahler, V
    Vrtala, S
    Kuss, O
    Diepgen, TL
    Cromwell, O
    Fiebeg, H
    Schuler, G
    Kraft, D
    Valenta, R
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S255 - S255
  • [9] Evaluation of native birch molecular allergen nBet v 1: major allergen for birch pollen allergy diagnosis
    Ordonez, M.
    Huynh, K.
    Rouhani, R.
    Evangelista, R.
    Jaggi, K.
    Hovance-Burns, D.
    Davoudzadeh, D.
    Ferrara, R.
    Pirrotta, L.
    Mari, A.
    Banik, U.
    ALLERGY, 2008, 63 : 513 - 513
  • [10] Ligand Recognition of the Major Birch Pollen Allergen Bet v 1 is Isoform Dependent
    von Loetzen, Christian Seutter
    Jacob, Thessa
    Hartl-Spiegelhauer, Olivia
    Vogel, Lothar
    Schiller, Dirk
    Spoerlein-Guettler, Cornelia
    Schobert, Rainer
    Vieths, Stefan
    Hartl, Maximilian Johannes
    Roesch, Paul
    PLOS ONE, 2015, 10 (06):